- Home
- NVAX
NVAX
Novavax Inc.
as 07-26-2024 4:00pm EST
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 2.0B | IPO Year: | 1995 |
| Target Price: | $19.00 | AVG Volume (30 days): | 7.5M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.53 - $23.86 | Next Earning Date: | 08-06-2024 |
| Revenue: | $996,609,000 | Revenue Growth: | -26.66% |
| Revenue Growth (this year): | 3.18% | Revenue Growth (next year): | -57.52% |
Stock Insider Trading Activity of Novavax Inc. (NVAX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| YOUNG JAMES F | NVAX | Director | Jun 21 '24 | Sell | $14.09 | 7,500 | $105,675.00 | 61,760 | SEC Form 4 |
| YOUNG JAMES F | NVAX | Director | Jun 18 '24 | Sell | $13.62 | 6,393 | $87,072.66 | 70,367 | SEC Form 4 |
| YOUNG JAMES F | NVAX | Director | Jun 18 '24 | Sell | $14.28 | 1,107 | $15,807.96 | 69,260 | SEC Form 4 |
| Dubovsky Filip | NVAX | President, R&D | Jun 17 '24 | Sell | $14.46 | 12,500 | $180,750.00 | 68,017 | SEC Form 4 |
| Dubovsky Filip | NVAX | President, R&D | Jun 17 '24 | Sell | $14.54 | 1,404 | $20,414.16 | 66,613 | SEC Form 4 |
| Dubovsky Filip | NVAX | President, R&D | May 14 '24 | Sell | $13.90 | 47,312 | $657,636.80 | 38,953 | SEC Form 4 |
Latest Novavax Inc. News
NVAX Breaking Stock News: Dive into NVAX Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Zacks
9 days ago
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Zacks
10 days ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Zacks
11 days ago
Wall Street Bulls Look Optimistic About Novavax (NVAX): Should You Buy?
Zacks
18 days ago
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
Simply Wall St.
19 days ago
Investors push Novavax (NASDAQ:NVAX) 6.0% lower this week, company's increasing losses might be to blame
MT Newswires
24 days ago
Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine
CNW Group
25 days ago
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Compare NVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVAX Novavax Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.